ABBOTT LABORATORIES (ABT) Shareholder Equity
- 2026-03-31: Preferred Stock, Value, IssuedUSD $0.00; Common Stock, Value, IssuedUSD $25.35B; Treasury Stock, Common, ValueUSD $16.93B; Accumulated Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Net of TaxUSD $-6.33B.
- 2025-12-31: Preferred Stock, Value, IssuedUSD $0.00; Common Stock, Value, IssuedUSD $25.53B; Treasury Stock, Common, ValueUSD $17.18B; Accumulated Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Net of TaxUSD $-5.93B.
- 2025-09-30: Preferred Stock, Value, IssuedUSD $0.00; Common Stock, Value, IssuedUSD $25.41B; Treasury Stock, Common, ValueUSD $16.88B; Accumulated Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Net of TaxUSD $-6.09B.
- 2025-06-30: Preferred Stock, Value, IssuedUSD $0.00; Common Stock, Value, IssuedUSD $25.28B; Treasury Stock, Common, ValueUSD $16.61B; Accumulated Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Net of TaxUSD $-5.96B.
ABBOTT LABORATORIES Shareholder Equity
Filed components and totals, with each concept and unit kept separate. Components can overlap; they are not added together. Missing disclosures remain (m). Original concept pages retain their detailed breakdowns and history.
| Period end | Preferred Stock, Value, Issued USD | Common Stock, Value, Issued USD | Treasury Stock, Common, Value USD | Accumulated Other Comprehensive Income (Loss), Foreign Currency Translation Adjustment, Net of Tax USD | Accumulated Other Comprehensive (Income) Loss, Defined Benefit Plan, after Tax USD | Accumulated Other Comprehensive Income (Loss), Net of Tax USD | Retained Earnings (Accumulated Deficit) USD | Stockholders' Equity Attributable to Parent USD | Stockholders' Equity, Including Portion Attributable to Noncontrolling Interest USD | Treasury Stock, Common, Shares shares | Treasury Stock, Value USD | AOCI, Debt Securities, Available-for-sale, Adjustment, after Tax USD | Common Stock, Value, Outstanding USD | Reclassification from Accumulated Other Comprehensive Income, Current Period, Net of Tax USD | Reclassification from Accumulated Other Comprehensive Income, Current Period, before Tax USD | Accumulated Other Comprehensive Income (Loss), Cumulative Changes in Net Gain (Loss) from Cash Flow Hedges, Effect Net of Tax USD | Treasury Stock, Shares shares |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-03-31 | $0.00 | $25.35B | $16.93B | $-6.33B | $14.00M | $-6.31B | $49.96B | $52.06B | $52.70B | 256.42M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2025-12-31 | $0.00 | $25.53B | $17.18B | $-5.93B | $1.00M | $-6.00B | $49.78B | $52.13B | $52.77B | 260.20M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2025-09-30 | $0.00 | $25.41B | $16.88B | $-6.09B | $566.00M | $-6.68B | $49.10B | $50.95B | $51.26B | 257.87M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2025-06-30 | $0.00 | $25.28B | $16.61B | $-5.96B | $555.00M | $-6.58B | $48.47B | $50.56B | $50.83B | 255.99M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2025-03-31 | $0.00 | $25.12B | $16.61B | $-6.96B | $581.00M | $-7.42B | $47.72B | $48.81B | $49.06B | 256.02M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-12-31 | $0.00 | $25.15B | $16.84B | $-7.50B | $611.00M | $-7.91B | $47.26B | $47.66B | $47.90B | 259.77M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-09-30 | $0.00 | $25.02B | $16.48B | $-6.43B | $1.35B | $-7.80B | $39.06B | $39.80B | $40.03B | 256.60M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-06-30 | $0.00 | $24.86B | $15.76B | $-6.93B | $1.36B | $-8.13B | $38.35B | $39.32B | $39.56B | 250.13M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2024-03-31 | $0.00 | $24.73B | $15.76B | $-6.89B | $1.37B | $-8.17B | $38.01B | $38.81B | $39.04B | 250.16M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-12-31 | $0.00 | $24.87B | $15.98B | $-6.50B | $1.38B | $-7.84B | $37.55B | $38.60B | $38.83B | 253.81M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-09-30 | $0.00 | $24.73B | $15.69B | $-7.13B | $1.51B | $-8.48B | $36.92B | $37.48B | $37.69B | 251.25M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-06-30 | $0.00 | $24.61B | $15.72B | $-6.65B | $1.50B | $-8.07B | $36.35B | $37.17B | $37.40B | 251.82M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2023-03-31 | $0.00 | $24.49B | $15.31B | $-6.59B | $1.49B | $-8.04B | $35.87B | $37.01B | $37.23B | 247.96M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2022-12-31 | $0.00 | $24.71B | $15.23B | $-6.73B | $1.49B | $-8.05B | $35.26B | $36.69B | $36.91B | 248.72M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2022-09-30 | $0.00 | $24.56B | $14.55B | $-7.27B | $2.50B | $-9.45B | $35.12B | $35.67B | $35.88B | 242.35M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2022-06-30 | $0.00 | $24.43B | $13.72B | $-6.26B | $2.55B | $-8.71B | $34.49B | $36.49B | $36.72B | 234.46M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2022-03-31 | (m) | $24.30B | $13.73B | $-5.95B | $2.61B | $-8.47B | $33.30B | $35.40B | $35.63B | 234.58M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-12-31 | $0.00 | $24.47B | $11.82B | $-5.84B | $2.67B | $-8.37B | $31.53B | $35.80B | $36.02B | 221.19M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-09-30 | (m) | $24.29B | $11.00B | $-5.62B | $3.66B | $-9.24B | $30.38B | $34.42B | $34.64B | 214.82M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-06-30 | (m) | $24.15B | $10.34B | $-5.23B | $3.74B | $-9.07B | $29.05B | $33.80B | $34.03B | 209.74M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2021-03-31 | (m) | $24.02B | $9.85B | $-5.39B | $3.79B | $-9.29B | $28.67B | $33.56B | $33.79B | 205.39M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-12-31 | (m) | $24.14B | $10.04B | $-4.86B | $3.87B | $-8.95B | $27.63B | $32.78B | $33.00B | 209.93M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-09-30 | (m) | $24.04B | $9.87B | $-5.60B | $3.42B | $-9.04B | $26.27B | $31.39B | $31.59B | 208.41M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-06-30 | (m) | $23.89B | $9.90B | $-5.71B | $3.45B | $-9.08B | $25.67B | $30.58B | $30.80B | 209.06M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2020-03-31 | (m) | $23.73B | $9.91B | $-6.07B | $3.48B | $-9.39B | $25.79B | $30.22B | $30.43B | 209.27M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-12-31 | (m) | $23.85B | $10.15B | $-4.92B | $3.54B | $-8.46B | $25.85B | $31.09B | $31.30B | 214.35M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-09-30 | (m) | $23.77B | $9.63B | $-5.18B | $2.65B | $-7.76B | $25.44B | $31.82B | $32.02B | 208.25M | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
| 2019-06-30 | (m) | $23.66B | $9.66B | $-4.70B | $2.68B | $-7.37B | $25.05B | $31.69B | $31.89B | 208.85M | (m) | (m) | (m) | (m) | 3 month · $26.00M 6 month · $75.00M | (m) | (m) |
| 2019-03-31 | (m) | $23.46B | $9.68B | $-4.79B | $2.70B | $-7.47B | $24.61B | $30.93B | $31.13B | 209.29M | (m) | (m) | (m) | (m) | (m) | $23.00M | (m) |
| 2018-12-31 | (m) | $23.51B | $9.96B | $-4.91B | $2.73B | $-7.59B | $24.56B | $30.52B | $30.72B | 215.57M | (m) | (m) | (m) | (m) | (m) | $52.00M | (m) |
| 2018-09-30 | (m) | $23.43B | $9.86B | $-4.63B | $2.42B | $-7.01B | $24.14B | $30.70B | $30.90B | 214.26M | (m) | (m) | (m) | (m) | (m) | $37.00M | (m) |
| 2018-06-30 | (m) | $23.32B | $9.91B | $-4.48B | $2.44B | $-6.91B | $24.08B | $30.58B | $30.77B | 215.26M | (m) | (m) | (m) | (m) | 3 month · $-2.00M 6 month · $-50.00M | $2.00M | (m) |
| 2018-03-31 | (m) | $23.22B | $9.95B | $-3.12B | $2.50B | $-5.73B | $23.86B | $31.40B | $31.60B | 216.14M | (m) | (m) | (m) | (m) | (m) | $-116.00M | (m) |
| 2017-12-31 | (m) | $23.21B | $10.22B | $-3.45B | $2.52B | $-6.06B | $23.98B | $30.90B | $31.10B | 222.31M | (m) | $-5.00M | (m) | (m) | (m) | $-84.00M | (m) |
| 2017-09-30 | (m) | $23.12B | $10.29B | $-3.71B | $2.19B | $-6.12B | $25.32B | $32.03B | $32.22B | 223.72M | (m) | $-123.00M | (m) | (m) | (m) | $-90.00M | (m) |
| 2017-06-30 | (m) | $23.01B | $10.36B | $-4.00B | $2.21B | $-6.25B | $25.20B | $31.60B | $31.79B | 225.29M | (m) | $13.00M | (m) | (m) | (m) | $-52.00M | (m) |
| 2017-03-31 | (m) | $22.89B | $10.38B | $-4.28B | $-2.24B | $-6.53B | $25.39B | $31.36B | $31.55B | 225.65M | (m) | $11.00M | (m) | (m) | (m) | $-15.00M | (m) |
| 2016-12-31 | (m) | $13.03B | $10.79B | $-4.96B | $2.28B | $-7.26B | $25.57B | $20.54B | $20.72B | 234.61M | (m) | $-69.00M | (m) | (m) | (m) | $49.00M | (m) |
| 2016-09-30 | (m) | $12.94B | (m) | $-4.42B | $-1.97B | $-6.53B | $25.16B | $20.78B | $20.90B | (m) | $10.79B | $-78.00M | (m) | (m) | (m) | $-60.00M | 234.65M |
| 2016-06-30 | (m) | $12.84B | (m) | $-4.51B | $-1.99B | $-7.22B | $25.88B | $20.68B | $20.80B | (m) | $10.82B | $-691.00M | (m) | (m) | (m) | $-33.00M | 235.27M |
| 2016-03-31 | (m) | $12.74B | (m) | $-4.41B | $-1.94B | $-6.85B | $25.65B | $20.72B | $20.84B | (m) | $10.82B | $-478.00M | (m) | (m) | (m) | $-25.00M | 235.34M |
| 2015-12-31 | (m) | $12.73B | $10.62B | $-4.83B | $1.96B | $-6.66B | $25.76B | $21.21B | $21.33B | 229.35M | $10.62B | $65.00M | (m) | (m) | (m) | $64.00M | 229.35M |
| 2015-09-30 | (m) | $12.64B | (m) | $-4.29B | $-2.13B | $-7.21B | $25.38B | $21.11B | $21.22B | (m) | $9.69B | $-900.00M | (m) | (m) | (m) | $108.00M | 208.81M |
| 2015-06-30 | (m) | $12.57B | (m) | $-3.64B | $-2.16B | $-5.00B | $25.16B | $23.01B | $23.13B | (m) | $9.72B | $696.00M | (m) | (m) | (m) | $100.00M | 209.26M |
| 2015-03-31 | (m) | $12.46B | (m) | $-4.83B | $-1.96B | $-5.61B | $24.74B | $21.87B | $21.99B | (m) | $9.72B | $65.00M | (m) | (m) | (m) | $64.00M | 209.37M |
| 2014-12-31 | (m) | $12.38B | (m) | $-2.92B | $-2.23B | $-5.05B | $22.87B | $21.53B | $21.64B | (m) | $8.68B | $1.00M | (m) | 12 month · $-25.00M | (m) | $99.00M | 186.89M |
| 2014-09-30 | (m) | $12.21B | (m) | $-1.77B | $-1.27B | $-2.98B | $22.34B | $22.89B | $22.99B | (m) | $8.68B | $1.00M | (m) | (m) | (m) | $63.00M | 186.92M |
| 2014-06-30 | (m) | $12.13B | (m) | $-675.00M | $-1.28B | $-1.95B | $22.14B | $23.60B | $23.70B | (m) | $8.71B | $9.00M | (m) | (m) | (m) | $-2.00M | 187.56M |
| 2014-03-31 | (m) | $12.03B | (m) | $-656.00M | $-1.30B | $-1.93B | $22.00B | $23.39B | $23.49B | (m) | $8.71B | $13.00M | (m) | (m) | (m) | $5.00M | 187.66M |
| 2013-12-31 | (m) | $12.05B | (m) | $-718.00M | $-1.31B | $-2.01B | $21.98B | $25.17B | $25.27B | (m) | $6.84B | $13.00M | (m) | 12 month · $-41.00M | (m) | $5.00M | 137.73M |
| 2013-09-30 | (m) | (m) | (m) | $-617.46M | $-2.39B | $-2.96B | $21.67B | $23.70B | $23.79B | (m) | $6.81B | $26.45M | $11.79B | (m) | (m) | $24.36M | 136.79M |
| 2013-06-30 | (m) | (m) | (m) | $-887.06M | $-2.41B | $-3.23B | $20.32B | $22.34B | $22.43B | (m) | $6.49B | $33.97M | $11.73B | (m) | (m) | $35.02M | 127.83M |
| 2013-03-31 | (m) | (m) | (m) | $527.48M | $2.44B | $-2.89B | $20.06B | $22.59B | $22.68B | (m) | $6.19B | $-31.53M | $11.62B | (m) | (m) | $-37.59M | 120.01M |
| 2012-12-31 | (m) | $11.76B | (m) | $-79.00M | $-3.60B | $-3.59B | $24.15B | $26.72B | $26.81B | (m) | $5.59B | $31.00M | $11.75B | (m) | (m) | $50.00M | 99.26M |
| 2012-09-30 | (m) | (m) | (m) | $247.19M | $2.62B | $-2.76B | $23.33B | $27.01B | $27.10B | (m) | $4.98B | $-31.48M | $11.42B | (m) | (m) | $-78.06M | 89.87M |
| 2012-06-30 | (m) | (m) | (m) | $1.07B | $2.65B | $-3.54B | $22.23B | $24.49B | $24.57B | (m) | $5.01B | $-48.83M | $10.82B | (m) | (m) | $-126.35M | 90.55M |
| 2012-03-31 | (m) | (m) | (m) | $-586.49M | $2.69B | $-1.94B | $21.31B | $25.45B | $25.54B | (m) | $4.30B | $-38.23M | $10.38B | (m) | (m) | $-124.92M | 79.05M |
| 2011-12-31 | (m) | (m) | (m) | $-72.00M | $-2.73B | $212.00M | $20.91B | $24.44B | $24.53B | (m) | $3.69B | $38.00M | $9.82B | (m) | (m) | $168.00M | 68.49M |
| 2011-09-30 | (m) | (m) | (m) | $1.22B | $2.14B | $-860.28M | $20.05B | $24.60B | $24.69B | (m) | $3.69B | $27.00M | $9.10B | (m) | (m) | $29.00M | 68.56M |
| 2011-06-30 | (m) | $9.01B | (m) | $2.72B | $2.17B | $577.78M | $20.51B | $26.38B | $26.47B | (m) | $3.71B | $35.00M | (m) | (m) | (m) | $-8.00M | 68.98M |
| 2011-03-31 | (m) | $8.84B | (m) | $2.36B | $2.19B | $182.05M | $19.32B | $24.63B | $24.72B | (m) | $3.72B | $25.00M | (m) | (m) | (m) | $-14.00M | 69.07M |
| 2010-12-31 | (m) | $8.74B | (m) | $-745.01M | $2.22B | $-1.37B | $19.22B | $22.68B | $22.77B | (m) | $3.92B | $-23.99M | $8.74B | (m) | (m) | $-84.33M | 72.71M |
| 2010-09-30 | (m) | $8.62B | (m) | $462.00M | $-2.10B | $-1.48B | $18.18B | $21.40B | $21.48B | (m) | $3.92B | $25.00M | (m) | (m) | (m) | $128.00M | 72.73M |
| 2010-06-30 | $0.00 | $8.50B | (m) | $690.00M | $-2.12B | $-2.63B | $17.98B | $19.91B | $19.99B | (m) | $3.94B | $21.00M | (m) | (m) | (m) | $158.00M | 73.17M |
| 2010-03-31 | $0.00 | $8.41B | (m) | (m) | (m) | $-975.67M | $17.37B | $20.86B | $21.01B | (m) | $3.95B | (m) | (m) | (m) | (m) | (m) | 73.24M |
| 2009-12-31 | $0.00 | $8.26B | (m) | $-3.04B | $2.16B | $854.07M | $17.34B | $23.14B | $23.19B | (m) | $3.31B | $-23.88M | $8.26B | (m) | (m) | $44.35M | 61.52M |
| 2009-09-30 | $0.00 | $8.01B | (m) | (m) | (m) | $498.97M | $16.15B | $21.34B | $21.37B | (m) | $3.32B | (m) | (m) | (m) | (m) | (m) | 61.73M |
| 2009-06-30 | $0.00 | $7.93B | (m) | (m) | (m) | $-6.62M | $15.30B | $19.88B | $19.92B | (m) | $3.34B | (m) | (m) | (m) | (m) | (m) | 62.04M |
| 2008-12-31 | $0.00 | $7.44B | (m) | $740.00M | $1.90B | $-1.16B | $13.83B | $17.48B | $17.52B | (m) | $2.63B | $17.00M | (m) | (m) | (m) | $-20.00M | 49.15M |
| 2007-12-31 | $0.00 | $6.10B | (m) | (m) | (m) | $2.08B | $10.81B | $17.78B | $17.82B | (m) | $1.21B | (m) | (m) | (m) | (m) | (m) | 30.94M |
| 2006-12-31 | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) | $14.05B | (m) | (m) | (m) | (m) | (m) | (m) | (m) | (m) |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| PFIZER INC (PFE) | United States | $162.042B | 31.94 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |